TransMedics Group, Inc.

As of November 7, 2025, TransMedics Group, Inc. is fairly valued with a P/E ratio of 96, a Price to Book Value of 17.67, and an EV to EBITDA of 66.22, indicating a premium compared to peers like CONMED Corp. and Integer Holdings Corp., while its PEG ratio of 0.53 suggests potential undervaluation in terms of growth.

As of November 7, 2025, TransMedics Group, Inc. is fairly valued with a P/E ratio of 96, outperforming the S&P 500 with a year-to-date return of 91.13%, despite having higher valuation ratios compared to peers like CONMED Corp. and Integer Holdings Corp.

As of October 31, 2025, TransMedics Group, Inc. shows a bullish trend supported by positive MACD and moving averages, despite mixed signals from the KST and a recent price decline, with impressive year-to-date and five-year returns compared to the S&P 500.

As of October 31, 2025, TransMedics Group, Inc. shows a bullish technical trend with strong momentum indicators, although some longer-term signals suggest caution.

As of October 31, 2025, TransMedics Group, Inc. shows a bullish trend supported by strong indicators like MACD and Bollinger Bands, despite some caution from KST and Dow Theory, and has outperformed the S&P 500 with a year-to-date return of 110.97%.

As of October 31, 2025, TransMedics Group, Inc. shows a bullish technical trend, supported by positive MACD and Bollinger Bands indicators, despite some caution from KST and Dow Theory indicators, and has significantly outperformed the S&P 500 with a year-to-date return of 110.97%.

As of October 17, 2025, TransMedics Group, Inc. is fairly valued with a P/E ratio of 96, a Price to Book Value of 17.67, and an EV to EBITDA of 66.22, outperforming the S&P 500 with an 88.66% year-to-date return.

As of October 17, 2025, TransMedics Group, Inc. is fairly valued with a P/E ratio of 96 and a favorable PEG ratio of 0.53, outperforming peers and the S&P 500 significantly over the past 3 and 5 years.

As of October 17, 2025, TransMedics Group, Inc. is fairly valued with a P/E ratio of 96, an EV to EBITDA of 66.22, and a PEG ratio of 0.53, outperforming peers like iRhythm Technologies and Axonics, and achieving a YTD return of 88.66% compared to the S&P 500's 13.30%.

As of October 10, 2025, TransMedics Group, Inc. shows a neutral trend with mixed signals; while it has a year-to-date return of 79.17% outperforming the S&P 500, it has underperformed over the past year with a return of -17.37%.

As of October 10, 2025, TransMedics Group, Inc. shows a neutral trend with mixed signals, as the weekly MACD is mildly bearish, monthly MACD is bullish, and the stock has underperformed the S&P 500 recently while outperforming it year-to-date and over the last three to five years.

As of October 10, 2025, TransMedics Group, Inc. shows a neutral technical trend with mixed indicators, including a mildly bearish weekly MACD and a bullish monthly MACD, while underperforming the S&P 500 recently but significantly outperforming over the year-to-date and three-year periods.

As of September 19, 2025, TransMedics Group, Inc. shows a bullish trend with strong monthly indicators, despite mixed weekly signals, and has returned 100.72% year-to-date, outperforming the S&P 500's 13.31%, although it has underperformed over the past year with a -24.15% return compared to the S&P's 16.64%.

As of September 19, 2025, TransMedics Group, Inc. is in a bullish trend with moderate strength, supported by positive indicators, despite some mild bearish signals on the weekly chart, and has outperformed the S&P 500 significantly year-to-date.

As of September 8, 2025, TransMedics Group, Inc. shows a mildly bullish trend with positive monthly indicators and a strong year-to-date return of 94.23%, despite a -22.35% return over the past year.

As of July 28, 2025, TransMedics Group, Inc. is fairly valued with a P/E ratio of 96 and a strong year-to-date return of 94.23%, positioning it favorably against peers despite its high valuation metrics.

As of May 9, 2025, TransMedics Group, Inc. is fairly valued with a high P/E ratio of 96, indicating it trades at a premium compared to peers like CONMED Corp., despite a strong year-to-date return of 104.54% and recent market caution.